DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2024” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Soft Tissue Sarcoma Research. Learn more about our innovative pipeline today! @ Soft Tissue Sarcoma Pipeline Outlook
Key Takeaways from the Soft Tissue Sarcoma Pipeline Report
Stay informed about the cutting-edge advancements in Soft Tissue Sarcoma Treatments. Download for updates and be a part of the revolution in oncology care @ Soft Tissue Sarcoma Clinical Trials Assessment
Soft Tissue Sarcoma Emerging Drugs Profile
Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-α, c-Kit, and FGFRs 1–3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells. More specifically, the mechanism involves the inhibition of the downstream ERK signaling pathway. Anlotinib has stronger anti-angiogenesis activity than that do other antiangiogenic agents (sunitinib and sorafenib). Currently, it is in Phase III stage of clinical trial evaluation to treat Soft Tissue Sarcoma.
Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Fibromun has previously been studied in clinical trials as monotherapy for systemic administration in patients with solid tumors and in melanoma patients using the Isolated Limb-Perfusion procedure. In preclinical models of sarcoma, Fibromun has, when combined with doxorubicin or dacarbazine (which are standard therapies for first line and third line sarcoma, respectively), cured all treated animals . Based on the encouraging results observed in the phase Ib study conducted in patients with metastatic Soft Tissue Sarcoma, three clinical trials with registration potential have started in Europe and in the United States. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Soft tissue sarcoma.
Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types. The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase IIα isoform achieves the anticancer effect, while inhibiting the topoisomerase IIβ isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase IIα isoform over the topoisomerase IIβ isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.
Learn more about Soft Tissue Sarcoma Drugs opportunities in our groundbreaking Soft Tissue Sarcoma Research and development projects @ Soft Tissue Sarcoma Unmet Needs
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Soft Tissue Sarcoma Products have been categorized under various Molecule types such as
Discover the latest advancements in Soft Tissue Sarcoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspectives
Scope of the Soft Tissue Sarcoma Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of Soft Tissue Sarcoma Pipeline on our website @ Soft Tissue Sarcoma Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09193216187Address:304 S. Jones Blvd #2432, City: Las VegasState: United StatesCountry: IndiaWebsite: https://www.delveinsight.com/